GAITHERSBURG, Md., Sept. 29 /PRNewswire-FirstCall/ -- MedImmune, Inc. has been named to Deloitte’s Maryland Technology Fast 50 program for the tenth consecutive year. The Technology Fast 50 is a ranking of the fastest growing technology companies in the area by Deloitte & Touche LLP. Rankings are based on the percentage growth over five years from 2001-2005.
“We are pleased to be recognized again by Deloitte & Touche as one of the area’s fastest growing technology companies,” said Lota S. Zoth, MedImmune’s chief financial officer. “Our continued inclusion in the Fast 50 program reflects the fact that MedImmune has doubled its revenues over the last five years, reaching $1.2 billion in 2005. Our goal is to continue to grow our business by aggressively investing in research and development activities. Toward this end, during 2005 we completed several late-stage clinical trials, started clinical testing on three new promising compounds, and expanded our product portfolio with almost a dozen new targets.
“MedImmune’s fast-paced growth continues in 2006,” Zoth said. “We submitted data to the FDA to expand our label indication for FluMist(R) (Influenza Virus Vaccine Live, Intranasal); we entered into an agreement with Infinity Pharmaceuticals to develop cancer drugs focused on two of the most attractive targeted therapy opportunities in cancer research today; we completed a Phase 3 study with our next-generation monoclonal antibody to prevent respiratory syncytial virus (RSV); and we initiated clinical testing with several new compounds, including those targeting lupus, RSV, parainfluenza virus type 3, B-cell lymphomas, and avian influenza viruses. We also received a $170-million contract from the U.S. Health and Human Services Department to expedite development of cell culture-based production of our flu vaccine, and earlier this month we broke ground on the first phase of a planned 700,000 square-foot expansion of our cell culture manufacturing facility in Frederick, Maryland.”
“To rank on Deloitte’s Technology Fast 50, companies must have phenomenal revenue growth over five years,” said Andrew Harrs, Deloitte’s Southeast regional managing partner for the Technology, Media and Telecommunications Industry Practice. “MedImmune has proven to be one of the fast-growth success stories in Maryland, and we applaud their dedication to making their vision a reality.”
The Maryland Technology Fast 50 program is presented by Deloitte and sponsored by Wilmer Cutler Pickering Hale and Dorr, NASDAQ and UK Trade & Investment. Media sponsors include PR Newswire and Washington SmartCEO magazine.
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology that contributes to a significant portion of the company’s operating revenues; or devotes a significant proportion of revenues to the research and development of technology.
Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on the Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.
About MedImmune
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,400 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company’s filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.
MedImmune, Inc.
CONTACT: Media: Kate Barrett, +1-301-398-4320, Investors: Peter Vozzo,+1-301-398-4358, both of MedImmune, Inc.
